Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8
5.2
Journals
Cancers
Special Issues
Quantitative Image Tissue Analysis Based on Multiplexed Platforms for Immuno-Oncology...
share announcement

Quantitative Image Tissue Analysis Based on Multiplexed Platforms for Immuno-Oncology Applications

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Immunology and Immunotherapy".

Deadline for manuscript submissions: 30 November 2024 | Viewed by 4082

Special Issue Editor

Dr. Edwin Roger Parra Cuentas

E-Mail Website
Guest Editor
Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
Interests: immune mechanisms; pathogenesis, lung cancer, immune profiling techniques; imaging platforms

Special Issue Information

Dear Colleagues,

Multiplexed imaging platforms to simultaneously detect multiple epitopes in the same tissue section as tyramide‐based immunofluorescence, cycling immunocytochemistry, epitope‐targeted mass spectrometry, or RNA detection emerged in the last years as potent tools to study tumor immune contexture. These revolutionary technologies provide a deep methodology for tumor evaluation in formalin-fixed and paraffin-embedded or frozen sections to improve the understanding of tumor microenvironment, new targets for treatment, prognostic and predictive biomarkers translational studies. Multiplexed imaging platforms allow for the identification of several antigens simultaneously from a single tissue section, core needle biopsies, tissue microarrays, and cytology. In last years, multiplexed imaging has improved the abilities to characterize the different types of cell populations in malignant and non-malignant tissues and their spatial distribution with clinical outcomes, permitting comprehensive studies of cell composition, functional state, and cell‐cell interactions, which suggest improved diagnostic benefit. In addition, multiplexed technologies associated with digital image analysis software offer a high-quality throughput assay to study cancer specimens at multiple time points before, during, and after treatment.

This Special Issue aims to provide extensive discussion in multiplexed imaging technologies for tissue immune-oncology analysis covering its fundamentals, material, and methods and their application in clinical and translational cancer research projects.

In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: Antibody standardization for multiplexed imaging platforms, comparison of methodologies to describe advantages and disadvantages, strategies and standardization of image analysis for multiplexed imaging platforms, development and optimization of immune profiling panels, orthogonal approaches for panel validation, cellular populations identification through biomarker co-expression, multiplexed imaging platforms for Biomarker discovery, spatial immune profiling as scoring system for research studies, algorithm creation and artificial intelligence application for multiplexed imaging platforms, best practices for delivery the results of multiplexed imaging analysis, importance of data size and data moralization for immune profiling studies, multiplexed imaging platforms to support cancer immunotherapy, multiplexed imaging platforms as potential application in the clinical side, application of multiplexed imaging platforms for cytology studies.

We look forward to receiving your contributions. 

Dr. Edwin Roger Parra Cuentas
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Dr. Edwin Roger Parra Cuentas
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • multiplexed imaging technologies
  • staining
  • imaging
  • algorithm creation
  • spatial analysis
  • clinical application

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

23 pages, 4656 KiB  
Article
The Immunological Landscape of M1 and M2 Macrophages and Their Spatial Distribution in Patients with Malignant Pleural Mesothelioma
by Caddie Laberiano-Fernandez, Camila Machado Baldavira, Juliana Machado-Rugolo, Auriole Tamegnon, Renganayaki Krishna Pandurengan, Alexandre Muxfeldt Ab’Saber, Marcelo Luiz Balancin, Teresa Yae Takagaki, Maria Aparecida Nagai, Vera Luiza Capelozzi and Edwin Roger Parra
Cancers 2023, 15(21), 5116; https://doi.org/10.3390/cancers15215116 - 24 Oct 2023
Viewed by 1450
Abstract
Background: Several tumor-associated macrophages (TAMs) have shown promise as prognosticators in cancer. Our aim was to validate the importance of TAMs in malignant pleural mesothelioma (MPM) using a two-stage design. Methods: We explored The Cancer Genome Atlas (TCGA-MESO) to select immune-relevant macrophage genes [...] Read more.
Background: Several tumor-associated macrophages (TAMs) have shown promise as prognosticators in cancer. Our aim was to validate the importance of TAMs in malignant pleural mesothelioma (MPM) using a two-stage design. Methods: We explored The Cancer Genome Atlas (TCGA-MESO) to select immune-relevant macrophage genes in MPM, including M1/M2 markers, as a discovery cohort. This computational cohort was used to create a multiplex immunofluorescence panel. Moreover, a cohort of 68 samples of MPM in paraffin blocks was used to validate the macrophage phenotypes and the co-localization and spatial distribution of these immune cells within the TME and the stromal or tumor compartments. Results: The discovery cohort revealed six immune-relevant macrophage genes (CD68, CD86, CD163, CD206, ARG1, CD274), and complementary genes were differentially expressed by M1 and M2 phenotypes with distinct roles in the tumor microenvironment and were associated with the prognosis. In addition, immune-suppressed MPMs with increased enrichment of CD68, CD86, and CD163 genes and high densities of M2 macrophages expressing CD163 and CD206 proteins were associated with worse overall survival (OS). Interestingly, below-median distances from malignant cells to specific M2a and M2c macrophages were associated with worse OS, suggesting an M2 macrophage-driven suppressive component in these tumors. Conclusions: The interactions between TAMs in situ and, particularly, CD206+ macrophages are highly relevant to patient outcomes. High-resolution technology is important for identifying the roles of macrophage populations in tissue specimens and identifying potential therapeutic candidates in MPM. Full article
(This article belongs to the Special Issue Quantitative Image Tissue Analysis Based on Multiplexed Platforms for Immuno-Oncology Applications)
►▼ Show Figures

Figure 1

15 pages, 3835 KiB  
Article
Cellular and Molecular Mechanisms of Liver Fibrosis in Patients with NAFLD
by Jessica I. Sanchez, Edwin R. Parra, Jingjing Jiao, Luisa M. Solis Soto, Debora A. Ledesma, Omar A. Saldarriaga, Heather L. Stevenson and Laura Beretta
Cancers 2023, 15(11), 2871; https://doi.org/10.3390/cancers15112871 - 23 May 2023
Cited by 1 | Viewed by 1934
Abstract
The expression of immune- and cancer-related genes was measured in liver biopsies from 107 NAFLD patients. The strongest difference in overall gene expression was between liver fibrosis stages F3 and F4, with 162 cirrhosis-associated genes identified. Strong correlations with fibrosis progression from F1 [...] Read more.
The expression of immune- and cancer-related genes was measured in liver biopsies from 107 NAFLD patients. The strongest difference in overall gene expression was between liver fibrosis stages F3 and F4, with 162 cirrhosis-associated genes identified. Strong correlations with fibrosis progression from F1 to F4 were observed for 91 genes, including CCL21, CCL2, CXCL6, and CCL19. In addition, the expression of 21 genes was associated with fast progression to F3/F4 in an independent group of eight NAFLD patients. These included the four chemokines, SPP1, HAMP, CXCL2, and IL-8. A six-gene signature including SOX9, THY-1, and CD3D had the highest performance detecting the progressors among F1/F2 NAFLD patients. We also characterized immune cell changes using multiplex immunofluorescence platforms. Fibrotic areas were strongly enriched in CD3+ T cells compared to CD68+ macrophages. While the number of CD68+ macrophages increased with fibrosis severity, the increase in CD3+ T-cell density was more substantial and progressive from F1 to F4. The strongest correlation with fibrosis progression was observed for CD3+CD45R0+ memory T cells, while the most significant increase in density between F1/F2 and F3/F4 was for CD3+CD45RO+FOXP3+CD8− and CD3+CD45RO−FOXP3+CD8− regulatory T cells. A specific increase in the density of CD68+CD11b+ Kupffer cells with liver fibrosis progression was also observed. Full article
(This article belongs to the Special Issue Quantitative Image Tissue Analysis Based on Multiplexed Platforms for Immuno-Oncology Applications)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop